BioSpace News Archive

NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on corporate activities.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the following statement clarifying November 17, 2019 as the true deadline for Velan Capital L.P.’s (“Velan”) consent solicitation.

Ryvu Therapeutics reported third quarter 2019 financial results and provided a corporate update.

Ten row crop growers each directed a $5,000 donation to a nonprofit organization of their choice as part of the Bayer Farm for Good™ Sweepstakes.

Study seeks to prove that Hoth’s and Zylo’s proprietary AEA-loaded Z-pods(TM) inhibits the development of CLE lesions in a standard animal model of lupus

Livestream Fundraiser to Feature Musical Performances, Celebrities & Influencers

Supports the first round of public private cooperative agreements to develop patient-centric quality measures in cancer for CMS

Platform Available to Research Community to Profile Novel Nonaddictive Analgesic Treatments

Stemline Therapeutics, Inc. announced that ELZONRIS, a novel targeted therapeutic directed to CD123, will be featured in three presentations, including an oral presentation of ELZONRIS clinical data in myelofibrosis, at the 2019 American Society of Hematology Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando, FL.

CTI BioPharma Corp. announced four poster presentations and one oral presentation supporting the Company’s pacritinib development program at the 61st American Society of Hematology Annual Meeting being held December 7- 10, 2019 in Orlando, Florida..